What is market sentiment?

Market sentiment is the overall attitude of investors toward a particular security or the financial market as a whole. It reflects whether investors are feeling bullish (optimistic) or bearish (pessimistic) based on price action, news flow, economic indicators, and collective psychology. Kinvestor tracks real-time market sentiment across major indices and individual equities.

How does financial news affect stock prices?

Financial news affects stock prices by shifting investor sentiment. Positive earnings reports, strong economic data, or favorable Fed decisions typically boost stock prices, while negative news can trigger sell-offs. The speed and magnitude of price moves depends on whether the news beats or misses market expectations.

What are stock market movers?

Stock market movers are stocks with significant price changes — either up (gainers) or down (losers) — within a trading session. Movers are typically driven by earnings reports, analyst upgrades or downgrades, macroeconomic news, or major corporate announcements. Kinvestor tracks the biggest movers in real time across the S&P 500, NASDAQ, and Dow Jones.

What is earnings season?

Earnings season is the period each quarter when publicly traded companies report their financial results. It occurs four times per year: January–February (Q4 results), April–May (Q1 results), July–August (Q2 results), and October–November (Q3 results). During earnings season, stocks often experience heightened volatility as results beat or miss analyst expectations.

What is financial intelligence?

Financial intelligence is the ability to understand and interpret financial data, market trends, news, and sentiment to make informed investment decisions. It combines real-time market data, news aggregation, sentiment analysis, and economic indicators into actionable insight. Kinvestor is a financial intelligence platform that aggregates these signals in one place.

◆ NeutralMBRX

Moleculin Announces Acceptance of Annamycin Data for Presentation at the 2026 American Society of Hematology (ASH) Annual Meeting

GlobeNewswire Inc.·November 4, 2026

Moleculin Biotech announced that data from its pivotal Phase 2/3 MIRACLE trial of Annamycin for relapsed or refractory acute myeloid leukemia (AML) has been accepted for presentation at the 2026 ASH Annual Meeting. First interim results from 45 randomized patients showed complete remission rates of 43% and 36% in the two Annamycin treatment arms compared to 12% in the placebo arm, with no observed cardiotoxicity. The independent Data Monitoring Committee recommended continuing the study without modification, with a comprehensive data readout expected in Q1 2027.

Read Full Article at GlobeNewswire Inc. →

← Back to Financial Intelligence